Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, dose- range finding, 12-week, double-blind, randomized, parallel group study to evaluate safety and efficacy of GRC 27864 in patients with moderate osteoarthritis pain

Next Previous
Trial Profile

A Phase 2, dose- range finding, 12-week, double-blind, randomized, parallel group study to evaluate safety and efficacy of GRC 27864 in patients with moderate osteoarthritis pain

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zaloglanstat (Primary)
  • Indications Musculoskeletal pain
  • Focus Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals Ltd

Most Recent Events

  • 14 Jul 2020 Status changed from active, no longer recruiting to completed.
  • 12 Nov 2019 According to an Ichnos Sciences media release, topline results are expected in the first half of 2020.
  • 04 Nov 2019 Status changed from recruiting to active, no longer recruiting according to an Ichnos Sciences media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top